company background image
CLN logo

Celon Pharma WSE:CLN Stock Report

Last Price

zł15.68

Market Cap

zł800.6m

7D

1.7%

1Y

-2.6%

Updated

23 Jun, 2024

Data

Company Financials +

CLN Stock Overview

An integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations.

CLN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for CLN from our risk checks.

Celon Pharma S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Celon Pharma
Historical stock prices
Current Share Pricezł15.68
52 Week Highzł17.94
52 Week Lowzł14.00
Beta0.83
11 Month Change0.51%
3 Month Change4.81%
1 Year Change-2.61%
33 Year Change-64.44%
5 Year Change-64.20%
Change since IPO-29.62%

Recent News & Updates

Recent updates

Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

Sep 24
Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans

Jul 13
Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans

We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow

Nov 04
We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow

We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth

Aug 04
We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth

Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly

May 23
Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly

Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)

Mar 02
Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)

Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Feb 09
Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?

Jan 20
Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?

Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain

Dec 24
Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain

Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet

Dec 03
Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet

Shareholder Returns

CLNPL PharmaceuticalsPL Market
7D1.7%1.5%3.1%
1Y-2.6%-9.5%21.4%

Return vs Industry: CLN exceeded the Polish Pharmaceuticals industry which returned -9.5% over the past year.

Return vs Market: CLN underperformed the Polish Market which returned 21.4% over the past year.

Price Volatility

Is CLN's price volatile compared to industry and market?
CLN volatility
CLN Average Weekly Movement3.2%
Pharmaceuticals Industry Average Movement5.0%
Market Average Movement5.2%
10% most volatile stocks in PL Market9.0%
10% least volatile stocks in PL Market3.3%

Stable Share Price: CLN has not had significant price volatility in the past 3 months.

Volatility Over Time: CLN's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002568Maciej Wieczorekwww.celonpharma.com

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland.

Celon Pharma S.A. Fundamentals Summary

How do Celon Pharma's earnings and revenue compare to its market cap?
CLN fundamental statistics
Market capzł800.57m
Earnings (TTM)-zł34.32m
Revenue (TTM)zł209.15m

3.8x

P/S Ratio

-23.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CLN income statement (TTM)
Revenuezł209.15m
Cost of Revenuezł63.59m
Gross Profitzł145.56m
Other Expenseszł179.88m
Earnings-zł34.32m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Sep 18, 2024

Earnings per share (EPS)-0.67
Gross Margin69.60%
Net Profit Margin-16.41%
Debt/Equity Ratio2.9%

How did CLN perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

-12%

Payout Ratio

Does CLN pay a reliable dividends?

See CLN dividend history and benchmarks
When do you need to buy CLN by to receive an upcoming dividend?
Celon Pharma dividend dates
Ex Dividend DateJun 27 2024
Dividend Pay DateJul 04 2024
Days until Ex dividend4 days
Days until Dividend pay date11 days

Does CLN pay a reliable dividends?

See CLN dividend history and benchmarks
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.